Neuphoria Therapeutics Inc. Payments for Restructuring
Neuphoria Therapeutics Inc. (NEUP) reported Payments for Restructuring of $1.22 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-09-18
- Neuphoria Therapeutics Inc. payments for restructuring for the quarter ending 2026-03-31 was $115.66K.
- Neuphoria Therapeutics Inc. payments for restructuring for the quarter ending 2025-12-31 was $973.33K.
- Neuphoria Therapeutics Inc. payments for restructuring for fiscal 2026 was $1.22M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 12 month |
|---|---|---|---|
| 2026-06-30 | $1.22M 10-K · filed 2026-09-18 | ||
| 2026-03-31 | $115.66K 10-Q · filed 2026-05-15 | $1.09M derived: sum of 2 quarters · filed 2026-05-15 | |
| 2025-12-31 | $973.33K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |